


Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Jan-2018
Document Type: NF Monographs
DocId: GUID-519592D5-2A0F-4DAE-995F-BF5521227949_3_en-US
DOI: https://doi.org/10.31003/USPNF_M726_03_01
DOI Ref: 9r7z8

© 2025 USPC
Do not distribute

Sodium Tartrate



Disodium L-tartrate;
Disodium (+)-2,3-dihydroxybutanedioic acid CAS RN®: 868-18-8.

DEFINITION
Sodium Tartrate contains NLT 99.0% and NMT 100.5% of sodium tartrate ($C_4H_4Na_2O_6$), calculated on the dried basis.

- IDENTIFICATION**
- **A.** [IDENTIFICATION TESTS—GENERAL, Sodium\(191\)](#): Meets the requirements
 - **B.** [IDENTIFICATION TESTS—GENERAL, Tartrate\(191\)](#): Meets the requirements

ASSAY

- **PROCEDURE**
Sample: 250 mg, previously dried at 150° for 3 h
Titrimetric system
(See [Titrimetry \(541\)](#).)
Mode: Direct titration
Titrant: 0.1 N Perchloric acid VS (in glacial acetic acid)
Endpoint detection: Potentiometric
Analysis: Dissolve the *Sample* in 150 mL of glacial acetic acid by stirring and heating to near the boiling point. Cool to room temperature. Titrate with 0.1 N perchloric acid VS (in glacial acetic acid) to a potentiometric endpoint. Perform a blank determination, and make any necessary adjustments. Each mL of 0.1 N perchloric acid is equivalent to 9.703 mg of sodium tartrate ($C_4H_4Na_2O_6$).
Acceptance criteria: 99.0%–100.5% on the dried basis

- SPECIFIC TESTS**
- **pH (791):** 7–9 (1 in 10 solution)
 - **Loss on Drying (731):** Dry a sample at 150° for 3 h: it loses 14.0%–17.0% of its weight.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in a tight container. No storage requirements specified.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
SODIUM TARTRATE	Documentary Standards Support	SE2020 Simple Excipients
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SE2020 Simple Excipients

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 32(6)

Current DocID: GUID-519592D5-2A0F-4DAE-995F-BF5521227949_3_en-US

Previous DocID: GUID-519592D5-2A0F-4DAE-995F-BF5521227949_1_en-US

DOI: https://doi.org/10.31003/USPNE_M726_03_01

DOI ref: [9r7z8](#)

OFFICIAL